Personalized intervention to reduce exposure to harmful chemicals
A Personalized Digital Intervention Program to Reduce Exposure to Endocrine Disrupting Chemicals Among a Child-Bearing Age Cohort
This study is testing whether a personalized program that includes chemical testing and education can help men and women of child-bearing age lower their exposure to harmful chemicals.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 18 Years to 44 Years |
| Sex | All |
| Sponsor | Million Marker Wellness, Inc. Industry-sponsored |
| Locations | 1 site (Reno, Nevada) |
| Trial ID | NCT06450951 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to determine if a personalized biomonitoring and educational intervention can effectively reduce exposure to endocrine disrupting chemicals (EDCs) in child-bearing aged men and women. Participants will undergo EDC testing and receive a report-back, along with access to an interactive online curriculum and live coaching. The study hypothesizes that this comprehensive approach will lead to greater reductions in EDC levels, improved environmental health literacy, and enhanced readiness to change behaviors compared to testing alone. The intervention seeks to empower individuals to understand and mitigate their environmental health risks.
Who should consider this trial
Good fit: Ideal candidates for this study are child-bearing aged men and women who are not pregnant and free from diabetes, kidney disease, or cancer.
Not a fit: Patients who are currently pregnant or have conditions that interfere with EDC metabolism may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly lower harmful chemical exposures and improve overall health outcomes for participants.
How similar studies have performed: Previous studies have shown promise in similar approaches to reducing chemical exposures and improving health literacy, indicating potential for success in this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * not pregnant, free from diabetes or known kidney disease or cancer (these conditions may interfere with EDC metabolism); able to understand written and spoken English; and willing to complete all study assessments. Exclusion Criteria: -
Where this trial is running
Reno, Nevada
- Renown Health — Reno, Nevada, United States (Recruiting)
Study contacts
- Study coordinator: Jenna Hua, PhD
- Email: founders@millionmarker.com
- Phone: 510-305-5690
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.